IFM Investors Pty Ltd Acquires Shares of 6,255 Alexion Pharmaceuticals, Inc. (ALXN)

IFM Investors Pty Ltd bought a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 6,255 shares of the biopharmaceutical company’s stock, valued at approximately $878,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC lifted its position in shares of Alexion Pharmaceuticals by 167.5% in the third quarter. Fieldpoint Private Securities LLC now owns 1,792 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 1,122 shares in the last quarter. Sterling Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the third quarter valued at approximately $306,000. Green Square Capital LLC purchased a new position in shares of Alexion Pharmaceuticals in the third quarter valued at approximately $489,000. Alkeon Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the third quarter valued at approximately $70,145,000. Finally, California Public Employees Retirement System lifted its position in shares of Alexion Pharmaceuticals by 3.5% in the third quarter. California Public Employees Retirement System now owns 463,579 shares of the biopharmaceutical company’s stock valued at $65,035,000 after acquiring an additional 15,588 shares in the last quarter. Institutional investors and hedge funds own 94.33% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $113.54 on Thursday. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $25,370.00, a price-to-earnings ratio of 22.88, a price-to-earnings-growth ratio of 1.22 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the previous year, the business earned $1.23 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.

Several equities analysts have recently weighed in on the company. Credit Suisse Group restated a “buy” rating and issued a $166.00 target price on shares of Alexion Pharmaceuticals in a research report on Tuesday. Leerink Swann reiterated a “buy” rating and set a $169.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 20th. Evercore ISI initiated coverage on Alexion Pharmaceuticals in a research report on Wednesday, August 16th. They set an “in-line” rating and a $137.00 price objective on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $155.47.

ILLEGAL ACTIVITY NOTICE: “IFM Investors Pty Ltd Acquires Shares of 6,255 Alexion Pharmaceuticals, Inc. (ALXN)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/14/ifm-investors-pty-ltd-acquires-shares-of-6255-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

What are top analysts saying about Alexion Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alexion Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit